EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The clinical relevance of RAS pathway gene mutations in childhood B-cell acute lymphoblastic leukemia

Xiaoyu Chen, Li Gao, Yongping Zhang, Yixin Hu, Jian Pan, Zhiheng Li, Jun Lu, Yizhen Li, Shaoyan Hu

Annals of Hematology · 13.07.2026 · 105 (11)

DOI: 10.1007/s00277-026-07164-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 13.07.2026. Verfasst von Xiaoyu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Children's Hospital of Soochow University, No. 92, Zhongnan Street, Suzhou, China. Hauptthemen laut MEDLINE: Mutation, fms-Like Tyrosine Kinase 3, Signal Transduction, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, National Key Research and Development Program of China, Suzhou Key project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Notably, FLT3 and RAS pathway gene mutations represent a significant proportion of childhood B-cell acute lymphoblastic leukemia (B-ALL) cases. Our study explores whether these patients have distinct clinical features and prognostic outcomes. METHODS: We retrospectively analyzed 488 pediatric B-ALL cases from the CCCG-ALL-2015 cohort using whole transcriptome sequencing to assess the clinical features of FLT3 mutations, RAS pathway alterations, and their cooperative effects. RESULTS: 192 patients (39.3%) carried at least one RAS pathway alterations, while 76 patients (15.6%) had FLT3 mutations. Strikingly, 6 of 11 NF1-mutated patients harbored concurrent FLT3 mutations. A significant correlation was observed between FLT3 and NF1 mutations (Phi coefficient = 0.16, χ² = 13.0, p < 0.001), NRAS and KRAS mutations (Phi coefficient = 0.19, χ² = 17.12, p < 0.0001), NRAS and PTPN11 (Phi coefficient = 0.138, χ² = 9.54, p = 0.0042). FLT3/NF1 co-mutated patients exhibited a higher frequency of abnormal karyotypes and had significantly poorer overall survival (OS) and event-free survival (EFS) (p < 0.05), particularly when compared to those without KMT2A rearrangements (p = 0.004 and p = 0.003, respectively). Collectively, RAS pathway alterations were not significantly associated with inferior OS or EFS. Multivariable Cox regression analysis confirmed that FLT3/NF1 co‑mutations were independently associated with inferior OS (HR = 12.39, 95% CI: 1.40-109.46, p = 0.024), and multivariable logistic regression analysis showed that they were also independently associated with Day 46 MRD ≥ 0.01% (OR = 9.50, 95% CI: 1.65-54.71, p = 0.01). CONCLUSION: Our findings suggest that FLT3/NF1 co-mutations-rather than other RAS pathway mutations, may be associated with adverse outcomes in pediatric B‑ALL, warranting further validation. TRIAL REGISTRATION: The study was conducted with approval from the Institutional Review Board of Children's Hospital of Soochow University (Approval number: 2019KS006).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mutationfms-Like Tyrosine Kinase 3Signal TransductionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins p21(ras)HumansFemaleChildMaleChild, PreschoolRetrospective StudiesInfantAdolescentGTP PhosphohydrolasesNeurofibromin 1Membrane ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 11

Stichwörter der Autor:innen

FLT3NF1B-cell acute lymphocytic leukemiaRAS pathway gene mutation

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, humanNRAS protein, humanGTP PhosphohydrolasesNF1 protein, humanNeurofibromin 1KRAS protein, humanMembrane ProteinsProto-Oncogene Proteins p21(ras)PTPN11 protein, human

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Children's Hospital of Soochow University, No. 92, Zhongnan Street, Suzhou, China.
  • Institute of Pediatric Research, Children's Hospital of Soochow University, No. 92 Zhongnan Street, SIP, Suzhou, China.
  • Department of Hematology and Oncology, Children's Hospital of Soochow University, No. 92, Zhongnan Street, Suzhou, China. drlujun_sz@163.com.
  • Department of Hematology and Oncology, Children's Hospital of Soochow University, No. 92, Zhongnan Street, Suzhou, China. liyz@suda.edu.cn.
  • Institute of Pediatric Research, Children's Hospital of Soochow University, No. 92 Zhongnan Street, SIP, Suzhou, China. liyz@suda.edu.cn.
  • Department of Hematology and Oncology, Children's Hospital of Soochow University, No. 92, Zhongnan Street, Suzhou, China. hushaoyan@suda.edu.cn.

Förderung

  • the National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Suzhou Key project

Zitieren

APA

Chen, X., Gao, L., Zhang, Y., Hu, Y., Pan, J., Li, Z., Lu, J., Li, Y., & Hu, S. (2026). The clinical relevance of RAS pathway gene mutations in childhood B-cell acute lymphoblastic leukemia. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07164-0

Vancouver

Chen X, Gao L, Zhang Y, Hu Y, Pan J, Li Z, et al. The clinical relevance of RAS pathway gene mutations in childhood B-cell acute lymphoblastic leukemia. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07164-0

BibTeX
@article{Chen2026,
  author = {Chen, Xiaoyu and Gao, Li and Zhang, Yongping and Hu, Yixin and Pan, Jian and Li, Zhiheng and Lu, Jun and Li, Yizhen and Hu, Shaoyan},
  title = {The clinical relevance of RAS pathway gene mutations in childhood B-cell acute lymphoblastic leukemia},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07164-0}
}
Kostenlos starten →